Latest / This Is Why with Dr. Busti
SGLT2 Inhibitors (eg, Empagliflozin) for Diabetes: Pharmacology Review
SGLT2 inhibitors (bexagliflozin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) don’t just lower glucose and A1C, but these meds have become relevant in cardiovascular disease and chronic kidney disease in the right patients also with type 2 diabetes (T2DM). In this lecture from This is Why, Dr. Busti will make the SGLT2 inhibitors make sense as they provide cardiorenal protection above their improvements in A1C.
You’ll learn how to:
- Mechanism of action (MOA): how SGLT2 blockade drives glucosuria, modest A1c reduction, weight loss, and BP lowering
- Clinical use: where SGLT2…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.